The anti-B7-H3 blocking antibody MJ18 does not recognize B7-H3 in murine tumor models.
Journal
bioRxiv : the preprint server for biology
Titre abrégé: bioRxiv
Pays: United States
ID NLM: 101680187
Informations de publication
Date de publication:
17 Nov 2023
17 Nov 2023
Historique:
pubmed:
28
11
2023
medline:
28
11
2023
entrez:
28
11
2023
Statut:
epublish
Résumé
The immune checkpoint molecule B7-H3 is regarded as one of the most promising therapeutic targets for the treatment of human cancers. B7-H3 is highly expressed in many cancers and its expression has been associated to impaired antitumor immunity and poor patient prognosis. In immunocompetent mouse tumor models, genetic deletion of B7-H3 in tumor cells enhances antitumor immune response leading to tumor shrinkage. The underlying mechanisms of B7-H3 inhibitory function remain largely uncharacterized and the identity of potential cognate(s) receptor(s) of B7-H3 is still to be defined. To better understand B7-H3 function
Identifiants
pubmed: 38014341
doi: 10.1101/2023.11.15.567261
pmc: PMC10680724
pii:
doi:
Types de publication
Preprint
Langues
eng
Subventions
Organisme : NCI NIH HHS
ID : P30 CA015083
Pays : United States
Références
Sci Transl Med. 2023 May 10;15(695):eadf6724
pubmed: 37163614
J Cell Mol Med. 2017 Sep;21(9):2199-2210
pubmed: 28401653
Nat Methods. 2016 Oct;13(10):823-7
pubmed: 27595404
Nat Immunol. 2001 Mar;2(3):269-74
pubmed: 11224528
Nat Med. 2020 May;26(5):712-719
pubmed: 32341579
Cancer Cell. 2019 Feb 11;35(2):221-237.e8
pubmed: 30753824
Nature. 2015 Feb 5;518(7537):27-9
pubmed: 25652980
Front Immunol. 2022 Aug 15;13:901349
pubmed: 36045668
Br J Cancer. 2009 Nov 17;101(10):1709-16
pubmed: 19844235
Cancers (Basel). 2020 Sep 18;12(9):
pubmed: 32961861
Genomics. 2003 Sep;82(3):365-77
pubmed: 12906861
Eur J Immunol. 2013 Jul;43(7):1735-44
pubmed: 23589339
J Immunol. 2011 Sep 15;187(6):3015-25
pubmed: 21832165
J Immunol. 2014 Jan 1;192(1):35-9
pubmed: 24285839
Cell Mol Immunol. 2020 Mar;17(3):227-236
pubmed: 31611650
Clin Transl Oncol. 2023 Apr;25(4):1067-1079
pubmed: 36512305
Clin Cancer Res. 2018 Jun 1;24(11):2653-2664
pubmed: 29530936
J Immunol. 2008 Sep 15;181(6):4062-71
pubmed: 18768862
Nat Methods. 2013 Aug;10(8):730-6
pubmed: 23921808
Cell Res. 2017 Aug;27(8):1034-1045
pubmed: 28685773
Pediatr Blood Cancer. 2011 Dec 1;57(6):921-9
pubmed: 21462302
Blood. 2012 Jun 14;119(24):5640-9
pubmed: 22535666
PLoS One. 2011;6(9):e24751
pubmed: 21931843
J Immunother Cancer. 2019 Dec 31;7(1):357
pubmed: 31892360
Eur J Immunol. 2022 May;52(5):753-759
pubmed: 35133670
Cancer Cell. 2017 Apr 10;31(4):501-515.e8
pubmed: 28399408
Oncoimmunology. 2021 Feb 17;10(1):1885778
pubmed: 33643696
Cancer Immunol Immunother. 2022 Jul;71(7):1549-1567
pubmed: 34739560
Clin Cancer Res. 2008 Aug 15;14(16):5150-7
pubmed: 18694993
Cancers (Basel). 2021 Sep 09;13(18):
pubmed: 34572755
Immunol Lett. 2007 Oct 31;113(1):52-7
pubmed: 17825429
Nature. 2015 May 21;521(7552):274-6
pubmed: 25993940
Cancer Immunol Res. 2022 Jan;10(1):56-69
pubmed: 34799346
Sci Adv. 2021 Nov 12;7(46):eabl7148
pubmed: 34757791
Sci Adv. 2021 Jan 15;7(3):
pubmed: 33523913
Mol Cancer Ther. 2020 Nov;19(11):2235-2244
pubmed: 32967924
Int J Cell Biol. 2012;2012:935173
pubmed: 22194750
Cancer Res. 2007 Aug 15;67(16):7893-900
pubmed: 17686830